The Pharma Data

AbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology

AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness AbbVie’s extensive experience in these fields alongside Tentarix’s groundbreaking Tentacles™…

Read MoreAbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology

BOTOX® Cosmetic (onabotulinumtoxinA) Unveils 2024 Grant Initiative to Empower Female Entrepreneurs

Today, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has officially launched the application process for its 2024 BOTOX® Cosmetic grant program, aimed at supporting women entrepreneurs. Following a successful partnership with IFundWomen in 2023, this year marks the second…

Read MoreBOTOX® Cosmetic (onabotulinumtoxinA) Unveils 2024 Grant Initiative to Empower Female Entrepreneurs

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of oral, small molecule protease inhibitors, has announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted the Innovation Passport…

Read MoreKalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

Argenx’s VYVGART Hytrulo Receives FDA Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the well-being of individuals with severe autoimmune conditions, has announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA)…

Read MoreArgenx’s VYVGART Hytrulo Receives FDA Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy

Diakonos Oncology Appoints Veteran BioPharma Senior Executive, Dr. Paul Lammers, to Board of Directors

Diakonos Oncology Corp. (“Diakonos”), a company in the clinical stage of immuno-oncology, has announced today the appointment of Dr. Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years of experience in the biotech and pharmaceutical industries, to its…

Read MoreDiakonos Oncology Appoints Veteran BioPharma Senior Executive, Dr. Paul Lammers, to Board of Directors

Health Canada Grants Approval for Remsima™ SC in Treating Inflammatory Bowel Disease (IBD)

Celltrion Healthcare Canada Limited has announced today that Health Canada has granted approval for Remsima™ SC as maintenance therapy for adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD). Remsima™ SC, a subcutaneous form of infliximab,…

Read MoreHealth Canada Grants Approval for Remsima™ SC in Treating Inflammatory Bowel Disease (IBD)

Lupin Granted U.S. FDA Approval for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate Tablets)

Leading global pharmaceutical company Lupin Limited (Lupin) has announced its receipt of approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for MinzoyaTM (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate…

Read MoreLupin Granted U.S. FDA Approval for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate Tablets)

EffRx Pharmaceuticals Enters Exclusive Licensing and Distribution Partnership with Lupin for BINOSTO® Commercialization in Vietnam & Philippines

EffRx Pharmaceuticals SA, a pharmaceutical company specializing in musculoskeletal and rare diseases medications, has disclosed the signing of an exclusive licensing and distribution arrangement for Binosto® in Vietnam and the Philippines with Lupin Limited (Lupin), a prominent global pharmaceutical company.…

Read MoreEffRx Pharmaceuticals Enters Exclusive Licensing and Distribution Partnership with Lupin for BINOSTO® Commercialization in Vietnam & Philippines